NCT00678730View on ClinicalTrials.gov

Pharmacogenetics of Cannabinoid Response

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 23, 2007

Primary Completion Date

September 11, 2014

Study Completion Date

September 11, 2014

Conditions
COMT Gene Polymorphism
Interventions
DRUG

delta 9 tetrahydrocannabinol

0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes

Trial Locations (1)

06516

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT00678730 - Pharmacogenetics of Cannabinoid Response | Biotech Hunter | Biotech Hunter